Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,092 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Computationally aided design of a high-performance organic semiconductor: the development of a universal crystal engineering core.
Petty AJ 2nd, Ai Q, Sorli JC, Haneef HF, Purdum GE, Boehm A, Granger DB, Gu K, Rubinger CPL, Parkin SR, Graham KR, Jurchescu OD, Loo YL, Risko C, Anthony JE. Petty AJ 2nd, et al. Among authors: gu k. Chem Sci. 2019 Oct 7;10(45):10543-10549. doi: 10.1039/c9sc02930c. eCollection 2019 Dec 7. Chem Sci. 2019. PMID: 32055377 Free PMC article.
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.
Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, Wang H, Yin Y, Wang X, Zhou X, Wang Y, Sun G, Wang J, Zhang L, Yang J, Qian J, Yan M, Liu X, Yi T, Cheng Y, Li M, Zang A, Wang S, Wang C, Wu X, Cheng J, Li H, Lin Y, Geng C, Gu K, Xie C, Xiong H, Wu X, Yang J, Li Q, Chen Y, Li F, Zhang A, Zhang Y, Wu Y, Nie J, Liu Q, Wang K, Mo X, Chen L, Pan Y, Fu P, Zhang H, Pang D, Sheng Y, Han Y, Wang H, Cang S, Luo X, Yu W, Deng R, Yang C, Keegan P. Jiang Z, et al. Among authors: gu k. Future Oncol. 2024 Dec 4:1-9. doi: 10.1080/14796694.2024.2430106. Online ahead of print. Future Oncol. 2024. PMID: 39628303
Utilizing an Opportunistic Clinical Study and Population-Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients.
Reeder JA, Creech CB, Nation RL, Gu K, Nalbant D, Wu N, Jimenez-Truque N, Fissell W, Rolsma SL, Fishbane N, Kirkpatrick CMJ, Patel PC, Watanabe A, Landersdorfer CB, Winokur P, An G. Reeder JA, et al. Among authors: gu k. J Clin Pharmacol. 2024 Dec 3. doi: 10.1002/jcph.6161. Online ahead of print. J Clin Pharmacol. 2024. PMID: 39628093
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Jin F, Gao H, An G, Ding C, Jiang X, Xiong J, Zhou X, Hu S, Lu P, Liu A, Guo S, Huang J, Zhu C, Zhao J, Gao B, Chen Y, Hu C, Zhang J, Zhang H, Zhao H, Wang Z, Ma X, Shi W. Zhou C, et al. Among authors: gu k. J Immunother Cancer. 2024 Nov 27;12(11):e009240. doi: 10.1136/jitc-2024-009240. J Immunother Cancer. 2024. PMID: 39608979 Free PMC article. Clinical Trial.
1,092 results